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CA125 is a high molecular weight glycoprotein that is
detected in tissues derived from foetal embryonic coelomic
epithelium (Kabawat et al., 1983). Serum CA125 levels are
elevated in 80% of patients with epithelial ovarian cancer
(Bast et al., 1983) although up to 70% of patients with small
volume disease will have false negative values (Schilthuis et
al., 1987; Niloff et al., 1985; Atack et al., 1986). Serum levels
may in part depend on a tumour-peritoneal cavity-blood
concentration gradient (Bast et al., 1981; Bergmann et al.,
1987; Fleuren et al., 1987) and as ovarian cancer is a disease
predominantly confined to the peritoneal cavity, peritoneal
washings may be a more sensitive marker of small volume
disease (Allegra et al., 1986). This has suggested the possi-
bility that peritoneal lavage fluid (PLF) CA125 may be a
useful staging tool at laparoscopy, and possibly at laparo-
tomy in the detection of sub-clinical disease.
As a preliminary investigation in the evaluation of perito-
neal lavage fluid (PLF) CA125 as a marker of minimal
residual disease in ovarian cancer, we wished to measure
CA125 levels in the peritoneal lavage fluid obtained from
healthy controls. Since there are isolated reports of serum
CA125 levels rising as a consequence of abdominal surgery
(Krebs et al., 1986, Cruickshank et al., 1987), it was essential
to assess the effect of surgery on PLF CA125 levels.
We performed the study in two groups of patients. In
group I, pre-operative serum and peri-operative peritoneal
lavage fluid were obtained from healthy pre-menopausal
women undergoing either hysterectomy for dysfunctional
uterine bleeding (n= 15) or laparoscopy (n =40). The indica-
tions for laparoscopy were sterilization (n=28), unexplained
pelvic pain (n=5), or infertility (n =7). No evidence of
disease, in particular endometriosis, was found at operation
although there was histological evidence of adenomyosis in
three of the hysterectomy specimens.
Peritoneal lavage was performed at laparoscopy after the
introduction of the laparoscope, whilst in patients under-
going hysterectomy, it was performed immediately after
opening the peritoneal cavity, great care being taken to
avoid contamination with blood. Peritoneal lavage was per-
formed with 11 0.9% saline that was left in situ for 5min
before a 20ml sample was taken and added to a plastic
universal container with 1 ml 3% sodium citrate. The operat-
ing table was repeatedly tilted to ensure as uniform a
distribution as possible.
Group II comprised 6 further patients undergoing hyster-
ectomy for dysfunctional bleeding (median age 36, range 31-
42). In this group, the anterior abdominal wall was opened
normally down to the peritoneum. Peritoneal lavage was
then performed, instilling 11 0.9% saline via a small perito-
neal incision just sufficient for a 12g urinary catheter to pass
through. A sample of PLF was obtained after a dwell time
of 5min. The peritoneum was then opened normally and a
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second sample of fluid taken 5min later. Peritoneal biopsies
were obtained for immunohistological studies. Serum CA125
levels were measured on each of the first 5 post-operative
days.
The blood and the PLF were centrifuged within 4h. The
serum and PLF supernatant were stored at -20°C until
assayed using a simultaneous sandwich IRMA (CIS,UK).
All measurements were performed in duplicate. PLF total
protein concentration was measured using a manual Ponseau
S dye binding method with colour measurement on a
Kontron UV spectrophotometer.
Immunohistochemical detection of CA125 in the perito-
neal biopsies was performed on snap-frozen material. OC125
murine monoclonal antibody was purchased in kit form
(CIS, UK) and an avidin biotin immunoperoxidase technique
was used in accordance with the manufacturer's instructions.
Natural logarithmic transformation of serum CA125, PLF
CA125 and protein values was employed to normalise their
positively skewed distributions. Student's t-test was used to
determine statistical significance of the differences between
means. In group I, a joint regression analysis of PLF CAI25
on patients' age was performed (Mather, 1964). In group II
the post-operative serum CA125 values for each patient were
analysed as a percentage change from the baseline pre-
operative values and for each time point means and 95%
confidence limits were computed. The analysis was per-
formed using a VAX 11/730 minicomputer at the West
Midlands CRC Clinical Trials Unit using programs from the
BMDP statistical software package (Dixon et al., 1985).
Immunohistochemical studies demonstrated CA125
positivity in the mesothelial cells lining the peritoneum in all
the specimens.
In group I, the CA125 concentration was significantly
higher in PLF obtained at laparotomy than that obtained at
laparoscopy whilst there was no significant difference
between the serum CA125 levels or the PLF protein concen-
tration (Table I).
Patients undergoing hysterectomy were significantly older
than the laparoscopy group. However, in a joint regression
analysis, there was no heterogeneity of regression between
the two groups (F1,51=0.4; P>0.2) and there was no evi-
dence for an association between PLF CA125 and age
(Fl51=0.2; P>0.20). There was no significant correlation
between PLF protein concentration and PLF CA125
(r=0.057; P=0.8) or between serum and PLF CA125 levels
(r=0.23; P=0.092).
In group II, PLF CA125 levels after the peritoneum had
been widely opened were significantly higher than when the
peritoneal lavage had been performed via a small peritoneal
incision (Table II). Despite this rise, there is no post-
operative elevation in serum CA125, alth6ugh the numbers
involved are small (Figure 1).
Using PLF CA125 values obtained at laparoscopy, a cut-
off point of 90 Uml-1 was determined, which would be
exceeded by only 1% of the normal population (i.e., mean
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Table I Comparison between laparoscopy and laparotomy patients in group 1
Laparoscopy [n=40] Laparotomy [n=15]
Mean CI Mean CI t53 P
Age 32 30-34 41 39-43 6.0b <0.001
Serum CA125' 18 15-22 21 16-27 0.9c 0.40
PLF CA125a 25 21-30 158 137-183 16.3b <0.001
PLF proteina 0.36 0.23-0.55 0.58 0.26-1.13 1.0C 0.31
aTests of significance carried out after log, transformation; bSeparate variance t-test; CPooled
variance t-test.
Table II PLF and post-operative serum CA125 results in group II patients
Post-operative serum CA125
PLF CA125 Day
Patient Small incision Large incision 0 1 2 3 4 5
1 47 68 21 19 22 26 24 23
2 26 106 54 61 58 80 80 68
3 41 94 53 41 37 34 33 35
4 60 277 24 30 34 56 49 50
5 21 46 20 18 20 24 22 26
6 36 137 24 18 20 22 22 16
Mean [95% CI] 39 [24-54] 121 [34-208]a
aPaired t,=2.7, P=0.038.
plus 2.3 times the standard deviation, using log, transformed
data).
It has been suggested that PLF CAl25 may be a useful
and sensitive staging tool in the management of ovarian
cancer if performed as an adjunct to laparoscopy (Allegra et
al., 1986). In that study, peritoneal lavage was performed
with 1.51 saline at the time of laparoscopy and an arbitrary
cut-off point of 33Uml-1 was chosen that correctly pre-
dicted the presence of residual disease in 86% of cancer
patients undergoing a second-look procedure. However, no
data on normal healthy women were reported.
Previous studies have shown that the assay of CA125 in
PLF has a similar working range and reproducibility as for
serum (Redman et al., 1988). The results reported here
indicate that incision of the peritoneum releases CA125 so
that higher levels PLF CA125 were found after laparotomy
than at laparoscopy. This is unlikely to be due to the
contamination of PLF with blood or tissue fluids containing
CA125 as the rise in CA125 is independent of the PLF
protein concentration.
Immunohistology confirms the findings of Kabawat et al.
(1983) that CA125 is expressed in normal adult peritoneum,
and may account for the elevation of serum CA125 observed
in a number of conditions that involve the peritoneum
(Malkasian et al., 1986; Barbieri et al., 1986; Halila et al.,
1986). Surgical trauma may therefore release CA125 and
indeed Cruickshank et al. (1987) noted serum CA125 eleva-
tion in five patients with ovarian cancer between the third
and the 16th post-operative day, though this may not have
been statistically significant. It is also apparent that in
ovarian and other cancers the extent of peritoneal involve-
ment strongly influences serum levels (Duk et al., 1986;
Schilthuis et al., 1987; Fleuren et al., 1987). The higher
serum levels observed in conjunction with peritoneal meta-
stases may be because the peritoneal basement membrane is
breached by tumour, enabling the tumour antigens to enter
into the peripheral circulation (Fleuren et al., 1987). How-
ever it is also possible that the peritoneum itself produces
and releases CA125 antigen as a reaction to metastatic
involvement, as non-malignant conditions that either inflame
or involve the peritoneum are associated with elevated serum






















Figure 1 Percentage changes of pre-operative serum CA125
following laparotomy (mean and 95% confidence intervals).
provide further evidence that non-malignant peritoneal
events release CA125 and illustrate further the non-
specificity of CA125 as a marker of ovarian cancer. In our
study, despite the elevation of PLF CA125 as a result of
peritoneal trauma there was no significant rise in the post-
operative serum levels but the numbers are small and further
study is warranted.
We hope to evaluate peritoneal lavage as a diagnostic
procedure in ovarian cancer patients both at laparoscopy
and in an out-patient context for the monitoring and
detection of small volume residual or progressive disease. As
a result of this preliminary study we conclude that control
PLF CA125 data must be collected at laparoscopy, not at
laparotomy. If a similar cut-off point is adopted as for
serum CA125 (i.e., to produce a false positive rate of 1% in
healthy controls; Bast et al., 1983) the upper limit of the
normal range is 90 U ml-1. Discriminant analysis using
control and cancer patients' data might give a more useful
cut-off point, especially as PLF CA125 is most likely to be
used in monitoring ovarian cancer and not as a population
screening tool. In addition, serum and PLF CA125 used in
conjunction with other diagnostic tests could be combined
using a discriminant analysis to produce an index that would
be more useful for predicting the presence of disease than
PLF alone.
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